NEW ORLEANS -- Patients experiencing major heart attacks had a lower risk of serious complications if they received a single injection of the investigational drug zalunfiban at first medical contact, ...
With new phase 3 data backing the ability of its emergency use zalunfiban to fend off further heart damage, CeleCor Therapeutics is one step closer to bringing a speedy new weapon to the race against ...
Perhaps the most intriguing implication of recent breakthrough research lies in an unexpected connection: the most rigorous mechanistic dissection of rapid antidepressant action identifies adenosine ...
After more than four decades with type 1 diabetes, I've tried half a dozen types of insulin that all struggled to keep pace with carbs at meals. I recently started using inhaled insulin (Afrezza), ...
Objectives This study compared the effectiveness of first-time use of faster aspart with rapid-acting insulin analogues in patients with type 1 diabetes (T1D) or type 2 diabetes (T2D). Design, setting ...
State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai 200237, China Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, ...
Share on Pinterest Experts say California’s new affordable insulin program is a breakthrough for people with diabetes. Getty Images California has launched a program to manufacture and sell lower-cost ...
A Prescription Drug User Fee Act target date of May 29, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License ...
Utah-based Civica will begin selling a type of long-acting insulin on Jan. 1, 2026, although it will not come from the nonprofit drug maker’s Petersburg facility. Civica announced Thursday it has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback